VERV News and Press, Verve Therapeutics Inc. From 04/02/24

2024-04-02 13:01:35 ET Read the full article on Seeking Alpha For further details see: XTIA, TPET and GSIT among mid-day movers

A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 63.6% to $0.168949 on volume of 119,634,330 shares C3is Inc. (CISS) rose 17.5% to $0.0424 on volume of 56,452,737 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 6.6% to $3.315 on volume...

2024-04-02 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...

2024-04-02 08:37:57 ET More on Pre-market losers & stocks. Hut 8 Mining Corp. (HUT) Q4 2023 Earnings Call Transcript From Bull To Bear: Recent Events Drove Me To Exit My Position In HUT 8 Hut 8 Post-Merger Comprehensive Thesis: JCapital Research Might Be Right ...

2024-04-02 07:34:50 ET More on Verve Therapeutics Verve's Proof-Of-Concept Data Doesn't Inspire Confidence Vectoring In On Verve Therapeutics Seeking Alpha’s Quant Rating on Verve Therapeutics Historical earnings data for Verve Therapeutics Fin...

Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thrombocytopenia seen in the sixth participant enrolled in 0.45 mg/kg dose cohort ...

2024-03-26 11:43:00 ET More on CRISPR Technology Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT...

2024-03-06 16:16:26 ET More on Metagenomi, Inc. Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps Metagenomi Begins Genetic Treatment IPO Rollout Moderna-backed Metagenomi sees stock fall 31% after $94M IPO Metagenomi prices initial off...

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on February 29, 2024, the company granted equity awards to thr...

Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of VERVE-101 in November 2023 Cash, Cash Equivalents and Marketable Securities of $624...